2024
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2016
Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
Jackson L, Bulloch K, Narayan D, Ariyan S, Gould Rothberg BE. Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy. Journal Of Clinical Oncology 2016, 34: 172-172. DOI: 10.1200/jco.2016.34.3_suppl.172.Peer-Reviewed Original ResearchBody mass indexDisease-free survivalWide local excisionCutaneous melanomaSurvival benefitSentinel lymphMass indexNormal-weight menNormal-weight womenSingle-institution cohortCox proportional hazardsNon-therapeutic interventionsFree survivalSLN statusWeight womenClinicopathologic factorsConsecutive patientsLocal excisionMultivariable analysisWeight menLifestyle factorsActive surveillanceSimilar survivalSurvival advantageMitotic count
1998
Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients
Ariyan S, Poo W. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 1998, 123: 335-343. PMID: 9526527, DOI: 10.1016/s0039-6060(98)70188-6.Peer-Reviewed Original ResearchConceptsElderly patientsYounger patientsIsolated perfusionMeaningful disease controlRegional isolated perfusionEvidence of diseaseHigh-dose chemotherapySeries of patientsIsolated limb perfusionMajor surgical proceduresNumber of patientsDisease-free controlsYears of ageSalvage of limbsSignificant palliationThird perfusionAggressive treatmentDose chemotherapyOlder patientsRecurrent diseaseSurvival benefitTransit diseaseSerious complicationsRecurrent tumorsLimb perfusion